What Does 4DMedical (ASX:4DX) Report About Lung-Imaging Adoption in FY26?

Sonal Goyal

27 October 2026 12:37 AM AEDT

What Does 4DMedical (ASX:4DX) Report About Lung-Imaging Adoption in FY26?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

4DMedical (ASX:4DX) disclosed operating revenue of AUD 7.1mn (up 21% YoY) for FY26.
The company reported adjusted net loss of AUD 32.9mn, with versus AUD 35.3mn in FY25.
The group reported 344,075 scans, up 77% YoY, delivery at 540 SaaS sites and year-end cash of AUD 278.0mn; statutory earnings included a material non-cash remeasurement charge.

4DMedical (ASX:4DX) operates in respiratory medical imaging technology and provides CT-based lung imaging and diagnostic SaaS platforms. Its latest material company statement, released on 28 August 2026, describes performance for FY26. The latest operational and financial disclosure is discussed separately from daily share-price trading.

What Did the 28 August 2026 Announcement Report?

In the statement published in September 2026, 4DMedical (ASX:4DX) disclosed operating revenue of AUD 7.1mn. The comparison was up 21% YoY. This is a company-reported performance indicator for FY26, and should be read in the context of the company’s business model and the accounting or operating definitions used in the release. The update also identifies adjusted net loss of AUD 32.9mn, with the associated comparison described as versus AUD 35.3mn in FY25. Those two measures capture different aspects of performance and are not interchangeable.

Financial Results and Operating Measures

The FY26 release presents operating revenue alongside adjusted net loss. For 4DMedical (ASX:4DX), reporting both is relevant because the business combines CT-based lung imaging and diagnostic SaaS platforms. Revenue and operating indicators describe the level of activity, while earnings or contract-based measures can reflect different timing, costs and recognition methods. The statement records the figures as AUD 7.1mn and AUD 32.9mn, respectively. Any comparison with previous reporting periods needs to use the same metric definition and reporting currency.

Operational Developments and Business Execution

The group reported 344,075 scans, up 77% YoY, delivery at 540 SaaS sites and year-end cash of AUD 278.0mn; statutory earnings included a material non-cash remeasurement charge. The disclosure sets out the company’s operational priorities and related performance indicators. Contract wins, recurring service delivery, product deployment and customer activity, where relevant, are separate indicators from recognised revenue. The financial outcome depends on the nature and timing of the services or products delivered.

Company Profile and Business Overview

4DMedical (ASX:4DX) is an Australian-listed business focused on respiratory medical imaging technology. Its activities include CT-based lung imaging and diagnostic SaaS platforms. The operating model shapes which activity indicators accompany reported earnings, including, where applicable, contract volumes, platform usage, licensing, adoption or project delivery. The FY26 release is therefore most usefully read using the specific figures attributed to 4DMedical (ASX:4DX), without importing metrics from unrelated companies.

Risks and Catalysts on Watch

Regulatory pathways, clinical adoption and cash deployment remain material, while adjusted loss must not be confused with the statutory result. The next reported period may also provide additional information on order conversion, customer demand, cash generation, financing, product implementation and the extent to which previously disclosed plans have proceeded. These factors will be reflected in subsequent company updates when further financial or operational information is reported.

Key Insights

The main factual developments for 4DMedical (ASX:4DX) are its FY26 disclosure of operating revenue at AUD 7.1mn, the reported adjusted net loss of AUD 32.9mn, and the operational information described above. The publication date was 28 August 2026. These measures should be retained with their precise period and accounting descriptions, especially when comparing the company with other ASX-listed small-cap businesses. Further updates may clarify how operating activity affects subsequently reported earnings and cash flow.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.